维立西呱治疗射血分数降低心力衰竭的研究进展

Research progress of vericiguat in the treatment of heart failure with reduced ejection fraction

维立西呱作为一种新型可溶性鸟苷酸环化酶刺激剂,通过干预细胞信号通路改善心肌和血管功能,降低心室重构、心肌肥厚、炎症和纤维化,延缓心力衰竭的进展。维立西呱不仅可以显著降低心力衰竭相关住院或心血管死亡等风险,而且患者对其耐受性和依从性良好,能够增加射血分数降低心力衰竭患者的额外获益并改善预后。该文将综述维立西呱在射血分数降低心力衰竭中的作用机制及研究进展。

As a novel soluble guanylate cyclase stimulator,vericiguat can improve myocardial and vascular function,reduce ventricular remodeling,myocardial hypertrophy,inflammation and fibrosis,and delay the progression of heart failure by interfering with cell signaling pathways.Vericiguat not only can significantly reduce the risk of heart failure-related hospitalization or cardiovascular death,but also is well tolerated and compliant by patients,which can increase the additional benefit and improve prognosis of patients with heart failure with reduced ejection fraction.This article will review the mechanism and research progress of vericiguat in heart failure with reduced ejection fraction.